HIV Diagnostics Market - By Test Type (Antibody Test, Viral Load Test, CD4 Test), By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings) & Forecast, 2022-2028

HIV Diagnostics Market size

HIV Diagnostics Market size surpassed USD 690 million in 2021 and is anticipated to foresee 0.8% CAGR from 2022 to 2028 to reach over USD 720 million in 2028 owing to the rising disease burden of HIV infections in developing countries. Favorable regulatory scenario and high investment in R&D activities by market players for the development of enhanced quality HIV diagnostics kits for home settings will fortify the market growth during the analysis period.
 

HIV remains a persistent problem for many African nations as well as other underdeveloped nations around the world. For instance, as per the data published by the UNAIDS, in 2020, around 670,000 new cases of HIV infection were recorded and over 20.6 million population were living with HIV in the eastern and southern Africa. Out of this nearly 10% individuals were unaware of their disease status.
 

Similarly, in Asia Pacific region, around 240,000 new cases of HIV were listed in 2020 and more than 5.8 million people were living with HIV infections. Thus, growing burden of HIV infections in underdeveloped and developing countries especially in African region will accelerate the demand for HIV diagnostics in forthcoming years.
 

The COVID-19 outbreak has adversely impacted on HIV diagnostics market in 2020. Many parts of the world adopted preventive lockdown to combat community transmission of the COVID-19 virus. This has resulted in a substantial decline in the count of HIV diagnostics procedures and patients visits in healthcare facilities thereby, negatively impacted on the market growth.
 

However, the market gained substantial growth in 2021 with fall in number of COVID-19 cases. The healthcare facilities implementing standard operating protocols, and a lower mortality rate related with COVID-19 have led to surge in elective procedures in the settings with reduced risk of infections. Thus, with declining COVID 19 patients is expected to experience significant market growth in near future.
 

Human immunodeficiency virus (HIV) is a virus that affects the immune system of the human body. HIV infection is transferrable and can be transmitted through contact with semen or vaginal fluids, infected blood and attacks the body's immune system. HIV diagnostics tests play a vital role in the precise diagnosis and treatment of an individual’s health. Growing availability of several HIV diagnostics tests worldwide will foster the HIV diagnostics market share.
 

Several developments and improved HIV diagnostics test kits will boost the market demand in near future

Continuous developments in the field of HIV diagnostics such as enhanced sensitivity for acute or early detection of HIV infections, thus impelling the market growth opportunities. Moreover, growing awareness and accessibility of improved HIV diagnostics kits especially in the low and middle-income countries will propel the HIV diagnostics market statistics.
 

Further, several regulatory authorities approving advanced products to combat high HIV disease burden will stimulate overall market growth. Also, several market participants are highly investing in R&D activities for development of advanced HIV diagnostics kits will augment the industry growth potential. With rising number of HIV prevalence rate along with surge in demand for HIV diagnotics tests in underdeveloped and developing countries, the market is predicted to witness lucrative growth opportunities reduce over the estimated time period.
 

HIV Diagnostics Market Analysis

HIV diagnostics market based on test type is classified into viral load test, antibody test, and CD4 test. Viral load test segment accounted for more than USD 450 million in 2021. Viral load test is a laboratory test to measure the viral load in patient’s body. These tests enhance treatment quality & better outcomes among infected patients.
 

High usage of viral load test is performed repeatedly to monitor viral load in the patients undergoing ART treatment. Now a days, these tests can be performed outside the laboratory settings by using advanced point-of-care molecular testing. Furthermore, strong product portfolio and presence of key industry players in the segment will drive segmental demand.
 

For instance, in 2019, Roche Diagnostics launched Cobas plasma separation card for viral load testing. This has strengthened company’s HIV diagnostics product portfolio. Thus, several developments in the segment will boost the adoption of viral load tests.
 

HIV diagnostics market based on end-use is classified into diagnostics laboratories, hospitals & clinics, home settings, and others. Diagnostic laboratories segment dominated the market and is estimated to witness 0.8% CAGR during forecast period. Continuous technological advancements in laboratory devices to enhance the testing outcomes will bolster segment growth. Growing awareness in patients regarding HIV diagnostics in urban & rural areas will fuel the segmental growth. High patient preference towards diagnostic laboratories owing to accurate diagnosis and patient care will foster the segmental expansion in forthcoming years.
 

Africa HIV diagnostics industry captured nearly 38% market share in 2021 and is poised to grow enormously over analysis timeframe. High prevalence rate of HIV infections in the African countries due to high rate of sex works, increasing rate of teenage pregnancy, lack of quality sex education are some major factors contributed to regional market growth.
 

Also, rising awareness initiatives by government and private players regarding HIV diagnostics and testing procedures, and growing presence of several industry players in this region will positively influence the overall market expansion. Moreover, growing adoption of point of care testing in several countries will further drive the adoption of HIV diagnostics tests in African countries.
 

HIV Diagnostics Market Share

Some of the notable industry players operating in the HIV diagnostics industry include

• Chembio Diagnostics
• OraSure Technologies
• Abbott Laboratories
• Becton Dickinson and company
• Cepheid
• Omega Diagnostics
• BIONEER CORPORATION
• Roche Diagnostics
• Biomerieux
• Qiagen

These market players are adopting numerous growth strategies such as collaboration, acquisition & merger, partnership and product launches to sustain market competition in HIV diagnostics market.
 

Some of the recent industry developments:

• In December 2020, Atomo Diagnostic signed a distribution agreement for HIV self-test with PrEP Health Pty Ltd. This has broadened customer reach & strengthened HIV diagnostics product portfolio.
   
• In November 2020, Hologic Inc. received approval for its HIV-1 viral load monitoring assay by the U.S. FDA. This has helped the company to expand its product portfolio in HIV diagnostics market.
   
• In May 2020, OraSure Technologies, Inc. acquired UrSure, Inc., a prominent company in laboratory testings. This acquisition has strengthened company’s product offerings in HIV diagnostics.
   

The HIV diagnostics market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2028, for the following segments:

Click here to Buy Section of this Report

By Test Type

• Antibody Test
• Viral load test
• CD4 test

By End-use

• Diagnostic Laboratories
• Hospitals & Clinics
• Home Settings
• Others

The above information is provided for the following regions and countries:

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
• Asia Pacific
  • India
  • China
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East
  • Iran
  • Saudi Arabia
  • Yemen
• Africa
  • South Africa
  • Mozambique
  • Nigeria
  • United Republic of Tanzania
  • Kenya
  • Uganda